NCIt definition : A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against
the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18),
with potential immunostimulating and antineoplastic activities. Upon administration,
osemitamab specifically targets, binds to and inhibits CLDN18.2 expressed on tumor
cells. This may kill CLDN18.2-expressing tumor cells by antibody-dependent cellular
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and inhibit cell
proliferation. CLDN18.2, a tight junction protein and stomach-specific isoform of
claudin-18, is overexpressed on a variety of tumor cells, but its expression in healthy
tissues is strictly confined to short-lived differentiated epithelial cells of the
gastric mucosa. Osemitamab is produced with reduced fucosylation.;
UNII : H14V1A2F4D;
CAS number : 2460539-61-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2460539-61-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)